The integrity of any modern healthcare system depends heavily on an unseen engine: the complex ecosystem of medical devices. From routine bedside monitors and haemodialysis units to life-critical technologies like mechanical ventilators, coronary stents and surgical robotics, modern medicine cannot function without precision technology. Yet across India, this vital machinery faces systemic threats, and ghastly incidents – such as the fatal ventilator failures in Amravati – serve as stark reminders of the cost of neglect.The intersection of contract lapses, unmonitored clinical practices and a historically lax regulatory approach to pre-market evaluation creates a perfect storm that jeopardises patient safety. Restoring public trust demands a comprehensive overhaul of administrative oversight, clinical accountability and device approval frameworks.Maintenance collapse: Administrative neglect and patient riskThe immediate vulnerability in public health delivery became starkly evident when the National Health Mission (NHM) abruptly suspended the Biomedical Equipment Management and Maintenance Programme (BEMMP) contract after its expiration in the Union Territory of Jammu and Kashmir. Designed to guarantee minimum uptime targets (typically 90% to 95%) through strict Service Level Agreements (SLAs) backed by financial penalty clauses, the BEMMP framework serves as the operational backbone for public hospital infrastructure.When such contracts lapse without a seamless re-tendering transition, peripheral and tertiary care facilities are left stranded. Hospitals are forced to rely on ad hoc, local interim arrangements to repair life-saving equipment. Such arrangements consistently fail to rationalise operations because they lack legal leverage, access to OEM-certified spare parts and the specialised engineering oversight required for high-risk equipment.When a ventilator or haemodialysis unit remains offline due to contractual delays, the cost is measured not in administrative overhead, but in human lives. Here are some recent examples:Amravati, Maharashtra: A catastrophic failure of ventilators at a District Women’s Hospital led to the heartbreaking deaths of at least three newborns before their fathers could even hold them, very recently on August 24 this year.Thiruvananthapuram, Kerala: A ventilator short-circuits triggered an Intensive Care Unit (ICU) fire, endangering the lives of 39 critically ill patients, who were evacuated in an emergency response at the Government Medical College in March this year.Jhansi, Uttar Pradesh: A short-circuit in an oxygen concentrator triggered a deadly fire at Maharani Laxmi Bai Medical College, claiming the lives of more than ten infants in November 2024.Unnecessary implants and the vacuum of auditingAdministrative failure in equipment upkeep is compounded by clinical oversight failures regarding high-risk medical implants. Across the healthcare landscape, cases of unnecessary medical procedures – most notably the indiscriminate deployment of coronary stents, pacemakers and orthopaedic implants – continue to surface. These practices thrive primarily because of a fundamental regulatory gap: the absence of systematic or random clinical auditing. Without robust institutional audits to cross-examine clinical indications against intervention outcomes, financial incentives often outpace clinical necessity.Transforming this compromised ecosystem requires an intentional shift across four core operational pillars. First, pre-market oversight. Devices historically cleared through simple predicate equivalence and minimal local data must be transitioned to mandatory, prospective and rigorously monitored clinical studies.Second, current absence of routine institutional oversight must give way to independent, unannounced registries and systematic procedural reviews across both public and private hospitals as part of post-market auditing. Third, rather than relying heavily on foreign approvals without local verification, regulators must enforce strict alignment with ISO 14155:2020 and ISO 13485 standards, under quality compliance regulations. Fourth, efficacy benchmarks. Fragmented, non-standardised, real-world tracking must be replaced by high-impact outcomes published in peer-reviewed international journals.Pre-market deficit and the role of MedTech CROsBeyond equipment maintenance and clinical auditing lies a deeper regulatory omission: allowing high-risk medical devices onto the market without sufficient clinical evidence. Historically, many devices reached Indian markets based on basic predicate comparisons rather than rigorous pre-market human trials. Bridging this gap requires specialised Contract Research Organizations (CROs) with proven credibility to generate high-quality clinical evidence.Medical devices cannot be evaluated like standard pharmaceuticals; they demand customised trial designs, specialised engineering parameters, strict adherence to ISO 14155 (‘Clinical Investigation of Medical Devices for Human Subjects’) and seamless regulatory alignment under the central purview of the Central Drugs Standard Control Organisation (CDSCO) and the Drugs Controller General of India (DCGI).Experienced operators in this specialised landscape – led by clinicians and research scientists – are best suited to transform regulatory outcomes. By focusing dedicatedly on medical devices rather than blurring lines with pharmaceutical studies, specialised CROs (alongside established global entities such as IQVIA, Parexel, ICON, PPD, Syneos Health and niche device players like CLICEBO) navigate the complex pathways needed to secure stringent international certifications, such as the European CE Mark (under EU MDR) and United States Food and Drug Administration (FDA) approvals.The portfolio of modern MedTech clinical trials ranges from bioresorbable coronary stents and structural heart devices to surgical robotics and remote heart-failure monitoring systems. A prime benchmark of this rigor is demonstrated by landmark multi-centre Indian trials like the TUXEDO study and its subsequent iterations, such as TUXEDO-2. By evaluating drug-eluting stents in challenging patient subsets, specifically diabetic populations with complex coronary disease, such studies generate definitive evidence that can shift international clinical guidelines. Without credible CRO infrastructure conducting high-calibre trials published in peer-reviewed journals, indigenous device innovations cannot establish international credibility or guarantee safety for domestic patients.Key actions for policy reformAddressing the medical device crisis requires a synchronised policy pivot across four key fronts:Institutionalise contract continuity: Public procurement agencies must mandate automated 12-month extension clauses in critical maintenance programs like BEMMP to ensure SLAs never lapse due to administrative inertia.Mandate clinical audits: Regulatory bodies must introduce random, independent clinical audits of procedural implantations to curb unneeded interventions and safeguard patient health.Enforce evidence-based market entry: Regulators must strictly enforce prospective, ISO-compliant clinical evaluations for high-risk (Class C and Class D) medical devices prior to commercial approval.Leverage dedicated MedTech CROs: Indian MedTech innovators must partner with certified CROs capable of conducting rigorous, peer-reviewed trials that stand up to global scrutiny.Fixing India’s medical device ecosystem requires moving past reactive crisis management toward a culture of systemic accountability. Modern medicine cannot deliver on its promise of healing when contractual oversight, unvetted implants or unchecked clinical practices compromise care. By embedding automated administrative fail-safes, enforcing mandatory clinical audits and anchoring device approvals in unassailable scientific evidence, regulatory bodies can build a resilient infrastructure where tragedies like Amravati never happen again.Upendra Kaul is an Indian Cardiologist and Researcher. Acknowledgement: The author acknowledges the contribution of Priyadarshini Arambam in writing this article. Arambam is the Director of Operations at Clicebo Solutions.